Decision Variables – Guideline Analytics

Shows truncated result set for single terms of decision variable when submitted to the UMLS. See filtered version in another tab.
Guideline Title	Conditional	Decision Variable	UMLS Codes
Heart Failure 2017 ACC/AHA/HFSA	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	Serial monitoring indicated	C3526969,C0015945
Heart Failure 2017 ACC/AHA/HFSA	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	selected patients who present with HF	C1144864
Heart Failure 2017 ACC/AHA/HFSA	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	patients presenting with dyspnea	C2368562
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	patients with HF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	no angina	C3248525,C3248257
Heart Failure 2017 ACC/AHA/HFSA	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	echocardiography is inadequate	C0013516
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	obesity	C3511720,C1314131,C3534868,C2724381,C4523705
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	diabetes mellitus	C3511720,C1314131,C3534868,C2724381,C4523705
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	tobacco use	C3511720,C1314131,C3534868,C2724381,C4523705
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	acute coronary syndrome	C0810126,C0520252
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	reduced EF	C0810126,C0520252
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	acute coronary syndrome	C0520252,C0810126
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	reduced EF	C0520252,C0810126
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	acute coronary syndrome	C0810126,C0520252
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	reduced EF	C0810126,C0520252
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome, statins should be used to prevent symptomatic Heart Failure and cardiovascular events.	acute coronary syndrome	C0810126
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	are on appropriate medical therapy	C3527118,C0918259,C1257928
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure should receive specific education to facilitate Heart Failure self-care.	Patients with HF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Exercise training (or regular physical activity) is recommended as safe and effective for patients with Heart Failure who are able to participate to improve functional status.	patients with HF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	Stage C patient with HFrEF	C3526570,C0973444,C0497660,C2065027,C3526564,C0497661,C0973439,C3526576,C0497659
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	NYHA class I-IV	C3526570,C0973444,C0497660,C2065027,C3526564,C0497661,C0973439,C3526576,C0497659
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I)	patient is NYHA class II–IV	C0497661
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III Heart Failure Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril then Discontinue ACEI or ARB; initiate ARNI	NYHA class II–III HF	C0497661
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	NYHA class III–IV	C0497661,C0497659,C1314210,C0497660
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	in black patients	C0497661,C0497659,C1314210,C0497660
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	NYHA class II–III	C3520484,C3248278,C0497660,C1736907,C3248277,C0497661,C1736638,C3248276,C0497659
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	left ventricular ejection fraction ?35%	C3520484,C3248278,C0497660,C1736907,C3248277,C0497661,C1736638,C3248276,C0497659
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	NYHA class II–IV	C0497659,C3520484,C3248278,C0497660,C1736907,C3248277,C0497661,C1736638,C3248276
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	left ventricular ejection fraction ?35%	C0497659,C3520484,C3248278,C0497660,C1736907,C3248277,C0497661,C1736638,C3248276
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	NYHA class II–III,	C0497659,C0497660,C0497661
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF with fluid retention	patients with HFrEF with fluid retention	C0523406
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended for all patients with Heart FailurerEF	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF who are ACE inhibitor–intolerant	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	patient with HFrEF	C3514891,C1444299,C0918259,C3526570,C3526576,C3526564,C3514892,C0198856,C1257928,C2065027,C0497702,C1610129,C1444296,C0150318,C0886115,C0973439,C1113679,C0973444
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	first-line therapy	C3514891,C1444299,C0918259,C3526570,C3526576,C3526564,C3514892,C0198856,C1257928,C2065027,C0497702,C1610129,C1444296,C0150318,C0886115,C0973439,C1113679,C0973444
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	stable patients	C1314212,C1314214,C1314210,C1314211,C1314213
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful in patients with Heart FailurerEF who cannot be given ACE inhibitors or ARBs	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	patients with chronic HFrEF without AF	C3701851,C0373220,C0373216
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	HFrEF patients	C1314214,C1314212,C1314214,C1314210,C1314210,C1314211,C1314213,C1314211,C1314213,C1314212
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	HFpEF patients	C1314214,C1314212,C1314214,C1314210,C1314210,C1314211,C1314213,C1314211,C1314213,C1314212
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	patient with HFrEF	C2065027,C0497702,C1610129,C0973439,C1113679,C0973444,C3526570,C3526576,C3526564
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	patient with HFrEF	C0973439,C1113679,C0973444,C3526570,C3526576,C3526564,C2065027,C0497702,C1610129
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor.	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered to patients with a history of angioedema.	patients with a history of angioedema	C1738525
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	patients with HFrEF	C1738525,C1314210
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	patients with NYHA class II–IV	C0497661
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	patients with HFrEF	C0858155,C1738525,C0202194,C1314210
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	potassium >5.0 mEq/L	C0858155,C1738525,C0202194,C1314210
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	patient preference	C3534860,C0497702,C1610129,C0973438,C3534859,C1113679,C0519731
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	patients with chronic HFrEF without AF	C0373220,C0373216,C3701851
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations for stage D starting on page 34).	patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment for patients with Heart FailurerEF.	patients with HFrEF.	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Systolic and diastolic blood pressure should be controlled in patients with Heart FailurepEF in accordance with published clinical practice guidelines to prevent morbidity.	patients with HFpEF	C1738525,C1314210
Heart Failure 2017 ACC/AHA/HFSA	Diuretics should be used for relief of symptoms due to volume overload in patients with Heart FailurepEF.	patients with HFpEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Management of AF according to published clinical practice guidelines in patients with Heart FailurepEF is reasonable to improve symptomatic Heart Failure.	patients with HFpEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	patients with hypertension	C1738525,C1314210,C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	patients with HFpEF	C1738525,C1314210,C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with Heart FailurepEF is ineffective.	patients with HFpEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nutritional supplements is not recommended for patients with Heart FailurepEF.	patients with HFpEF	C1738525,C1314210
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	sinus rhythm	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	NYHA class II, III, or ambulatory class IV symptoms	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	sinus rhythm	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	NYHA class III/ambulatory class IV symptoms on GDMT	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	sinus rhythm	C0497661,C0191654,C0869682,C3669066,C3513226,C0189160,C3702146,C0337422,C3520151,C3513194
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	NYHA class II, III, or ambulatory class IV symptoms on GDMT	C0497661,C0191654,C0869682,C3669066,C3513226,C0189160,C3702146,C0337422,C3520151,C3513194
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients on GDMT who have LVEF of ?35% and are undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	patients on GDMT	C1314210
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	sinus rhythm	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	and NYHA class III/ambulatory class IV on GDMT	C0191654,C0869682,C3669066,C0497660,C3513226,C0189160,C3702146,C0497661,C0337422,C3520151,C3513194,C0497659
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	sinus rhythm	C0191654,C0869682,C3669066,C3513226,C0189160,C3702146,C0337422,C3520151,C3513194
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	sinus rhythm	C0191654,C0869682,C3669066,C3513226,C0189160,C3702146,C0337422,C3520151,C3513194
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	hospitalized patients	C1314211,C1314213,C1314130,C1314212,C1314214,C1314210,C1144864
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	who present with low blood pressure	C1314211,C1314213,C1314130,C1314212,C1314214,C1314210,C1144864
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	patient with HF	C2065027,C0497702,C1610129,C0973439,C1113679,C0973444,C3526570,C3526576,C3526564
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	hospitalized patients	C1616290,C1314210,C3516497,C0005800,C3516500,C0373690,C1314130,C1314211,C1314213,C3516393,C0005841,C3516489,C0373570,C1314212,C1314214,C1609549,C0373984,C0371802
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	low blood pressure	C1616290,C1314210,C3516497,C0005800,C3516500,C0373690,C1314130,C1314211,C1314213,C3516393,C0005841,C3516489,C0373570,C1314212,C1314214,C1609549,C0373984,C0371802
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	carefully selected patients	C0520255,C3865445,C3512174,C2236411,C0374911,C0520255,C0520261,C4291714,C0038900,C2066451,C0150318,C1610129,C3512176,C3705624,C2066451,C0150318,C1610129,C3701854,C3520509,C3869420,C3527100,C0520256,C1314210,C3512175,C3869420,C3527100,C0520256,C0038897,C3701638,C0282493,C2236411,C0374911
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	device management	C0520255,C3865445,C3512174,C2236411,C0374911,C0520255,C0520261,C4291714,C0038900,C2066451,C0150318,C1610129,C3512176,C3705624,C2066451,C0150318,C1610129,C3701854,C3520509,C3869420,C3527100,C0520256,C1314210,C3512175,C3869420,C3527100,C0520256,C0038897,C3701638,C0282493,C2236411,C0374911
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	surgical management	C0520255,C3865445,C3512174,C2236411,C0374911,C0520255,C0520261,C4291714,C0038900,C2066451,C0150318,C1610129,C3512176,C3705624,C2066451,C0150318,C1610129,C3701854,C3520509,C3869420,C3527100,C0520256,C1314210,C3512175,C3869420,C3527100,C0520256,C0038897,C3701638,C0282493,C2236411,C0374911
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	during initial evaluation	C3513831,C3534876,C2018131,C0191235,C3516661,C3521208,C1971424,C0846574
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity.	Patients with HF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	If patients are already receiving loop diuretic therapy, the initial intravenous dose should equal or exceed their chronic oral daily dose	patients are receiving loop diuretic therapy	C3248300
Heart Failure 2017 ACC/AHA/HFSA	The effect of Heart Failure treatment should be monitored with careful measurement of fluid intake and output, vital signs, body weight that is determined at the same time each day, and clinical signs and symptoms of systemic perfusion and congestion. Daily serum electrolytes, urea nitrogen, and creatinine concentrations should be measured during the use of intravenous diuretics or active titration of Heart Failure medications.	patients with HF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Ultrafiltration may be considered for patients with obvious volume overload to alleviate congestive symptoms and fluid weight.	patients with obvious volume overload	C3865936
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	before hospital discharge,	C4291932,C2362761,C4291934
Heart Failure 2017 ACC/AHA/HFSA	Scheduling an early follow-up visit (within 7–14 days) and early telephone follow-up (within 3 days) of hospital discharge is reasonable.	(within 3 days) of hospital discharge	C3517375,C0374894,C3702191
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurerEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg.	Patients with HFrEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurepEF and persistent hypertension after management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg	Patients with HFpEF	C1314210,C1738525
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	In patients with cardiovascular disease	C3517193,C4067660,C0973439,C4291860,C0200101,C0973444,C3704075,C4291859,C3526717,C4291861
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	obstructive sleep apnea	C3517193,C4067660,C0973439,C4291860,C0200101,C0973444,C3704075,C4291859,C3526717,C4291861
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	central sleep apnea	C3704075,C4067657,C4067654,C4067649,C4292062,C4067659,C4067651,C4291861,C3517193,C4067656,C4067652,C4291859,C4292061,C4067658,C4067650,C4291860,C0200101,C4067653,C4292059,C4067660,C4292060,C4067655
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	with angina	C3248257,C3248525